Here's one:
Oral albuterol dosing during the latter stages of a resistance exercise program.Caruso JF, Hamill JL, De Garmo N.Healthcare Research Associates Inc., Orlando, Florida 32819, USA.
Subjects performed isoload variable resistance exercise (REX) 3 days per week. After 10 weeks, they received a double-blind albuterol (n = 11) or placebo (n = 11) capsule assignment with no crossover and continued training. During the first week of capsule administration, dosages were increased from 4 mg to 16 mg daily and then maintained for 14 days. At weeks 0, 10, and 13, we measured upper arm and thigh cross-sectional area, knee and elbow extensor and flexor (KE, KF, EE, EF) strength at 3 angular velocities, and lean body mass. Data after 10 weeks showed insignificant between-group differences. From weeks 10-13, as subjects continued REX training, albuterol evoked higher (p < 0.05) KE-KF strength gains at multiple velocities versus placebo dosing. A higher lean body mass trend also occurred with albuterol from weeks 10-13. Results suggest that albuterol augments REX to provide greater strength gains from hypertrophic factors than an REX-placebo assignment.
Here's another showing Albuterol's positive effects on cholesterol.
Effects of oral albuterol on serum lipids and carbohydrate metabolism in healthy men.Maki KC, Skorodin MS, Jessen JH, Laghi F.
Edward Hines, Jr, Veterans Affairs Hospital, Hines, IL, USA.
beta(2)-Selective adrenergic agonists are used in the management of bronchial asthma and preterm labor. Due to their ability to increase muscle strength and size in animal models, new applications for these agents are also being explored for neuromuscular disorders and in rehabilitation. However, the effects of long-term beta(2)-agonist administration on lipoprotein and carbohydrate metabolism are incompletely understood. This investigation evaluated the effects of a beta(2)-agonist, albuterol, on serum lipids and carbohydrate homeostasis in eight healthy nonsmoking men aged 24 to 61 years. Collection of fasting blood samples was completed in duplicate on separate days at baseline, during 14 days of oral albuterol administration (Proventil Repetabs, 8 mg twice daily; Schering Pharmaceuticals, Kenilworth, NJ) and during a 7-day washout period. Carbohydrate homeostasis was evaluated using the minimal model technique at the end of the baseline and albuterol periods. Fasting glucose and insulin, intravenous glucose tolerance, acute insulin response to intravenous glucose (AIRg), insulin sensitivity (Si), and glucose effectiveness (Sg) were not significantly changed during albuterol administration. Significant alterations (P < or = .02) were observed in total cholesterol ([TC] -9.1% +/- 2.5%), low-density lipoprotein cholesterol ([LDL-C] -15.0% +/- 2.9%), and high-density lipoprotein cholesterol ([HDL-C] +10.4% +/- 3.2%) concentrations, as well as the TC/HDL-C (-17.4% +/- 2.6%) and LDL-C/HDL-C (-22.9% +/- 2.4%) ratios. During washout, TC and LDL-C returned to baseline levels, whereas HDL-C remained elevated by 5.8% +/- 2.4% (P < .05). Thus, albuterol administration was associated with favorable changes in the serum lipid profile without marked impairment of glucose tolerance or its physiologic determinants.
